All In Biotech

BLA 761433 · Janssen Biotech

Rybrevant Faspro

Amivantamab and Hyaluronidase-Lpuj · Endoglycosidase

Priority review

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Dec 17, 2025

Approved uses

2

Original approval plus efficacy supplements

Registered trials

52

8 Phase 3, 19 recruiting

FAERS reports

306

207 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 5, 2026.

RYBREVANT FASPRO is a combination of amivantamab, a bispecific EGF receptor-directed and MET receptor-directed antibody, and hyaluronidase, an endoglycosidase indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1.1 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. ( 1.3 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1.4 ) as a single agent for the treatment of adult patients with recurrent or metastatic HNSCC whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. Limitations of use: RYBREVANT FASPRO is not indicated as a treatment for patients with OPSCC that is HPV-associated (i.e., by p16 IHC). ( 1.5 ) This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 ) 1.1 First-Line Treatment of NSCLC with...

Mechanism: Amivantamab is a bispecific antibody that binds to the extracellular domains of EGFR and MET. In in vitro and in vivo studies, amivantamab was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 19 deletions, exon 21 L858R substitutions, and exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity (ADCC) and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 5, 2026 Supplement 2 · Efficacy · priority review LabelLetter
  • Dec 17, 2025 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LetterLabel
2 products under this application
  • RYBREVANT FASPRO · AMIVANTAMAB AND HYALURONIDASE-LPUJ 14ML · INJECTION, · Prescription
  • RYBREVANT FASPRO · AMIVANTAMAB AND HYALURONIDASE-LPUJ 10ML · INJECTION, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amivantamab" as an intervention, any sponsor and status, largest first.

All 52 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash47
  • infusion related reaction32
  • paronychia29
  • off label use22
  • nausea17
  • stomatitis17
  • pyrexia14
  • administration related reaction13
  • decreased appetite13
  • pruritus12
  • cytopenia11
  • fatigue11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20251
2026305

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 53 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.